China has learned the hard way that infectious diseases don't respect borders. From SARS to COVID, rapid diagnosis is key to controlling outbreaks. The China rapid diagnostics market research shows that infectious disease testing is the fastest‑growing application, with a CAGR above 10%. Why? Because the government has invested heavily in surveillance and point‑of‑care testing.

What's new? Multiplex tests — a single swab that checks for flu, COVID, RSV, and even strep. The China rapid diagnostics market trends highlight that professional kits are the fastest‑growing product type in this segment, because hospitals and clinics need accurate, high‑volume testing. But OTC infectious disease tests (like HIV self‑tests) are also gaining ground, reducing stigma.

Technology is key. CRISPR‑based rapid tests (cheap, paper‑strip) are being developed in Chinese labs. They could revolutionise outbreak detection in rural areas.

The message: rapid infectious disease testing saves lives. But it's only useful if people use it and act on the results. That means education, accessibility, and trust. China is making progress, but there's still a long way to go.